Leukapheresis and Leukopaks Market and , By Type (Leukapheresis Disposables, Leukapheresis Devices), By Application (Research Applications, Therapeutic Applications), End User (Blood Component Providers and Blood Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospital and Transfusion Centers); Leukopaks Market, by Type (Mobilized Leukopaks, Non-Mobilized Leukopaks, Diseased Leukopaks, Isolated PBMCs), Indication (Acute Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Lymphoma, Pancreatic Cancer, Hepatocellular Carcinoma, Other), By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations), and Region (North America, Europe, Asia Pacific, Middle East & Africa, South America) — Industry Trends and Forecast to 2030

The Global Leukapheresis Market has been estimated to reach a value of USD 53.5 million in 2021 and is projected to grow at a CAGR of 43.9% during the forecast period. Leukapheresis is a specially modified apheresis technique designed to remove leukocyte and return the remaining cells (granulocytes, platelets, red blood cells) to the donor. Leukopaks (LPs) are leukapheresis samples obtained from healthy peripheral blood. Leukopaks market is subpart of leukapheresis market. Demand for leukopaks in clinical trials research is expected to contribute to market growth. Additionally, rising prevalence and incidence of leukemia, mortality rates due to leukemia, and increasing demand for blood donations are expected to contribute to market growth during the forecast period.

Leukapheresis is performed in CAR T-cell therapy, chronic lymphocytic leukemia (CLL), chemotherapy-induced leukopenia, and systemic infections associated with granulocytopenia. The separation of white blood cells from the blood sample, which is involved with the body’s immune system, is done with a medical procedure called leukapheresis. It is associated with various risks, and hence it is important to discuss beforehand for the procedures. Leukapheresis is similar to apheresis where platelets or red blood cells are extracted from blood, and the remaining blood is sent to the body’s blood circulation. High white blood cells in the body can result in chronic blood cancers like chronic lymphocytic leukemia (CLL), and thus leukapheresis is important to be performed.

Obtaining blood cells through leukapheresis for research & development activities and academic purposes will boost the market growth. For instance, in May 2020, a researcher at the University of Houston was working on developing a device by adapting microfluidic technology to enable leukapheresis in babies. The researcher also got a grant of USD 1.6 million from the National Heart, Lung, and Blood Institute.

Furthermore, collaborations and regulatory approvals will support market growth. For instance, in January 2019, Cascade Regional Blood Services and Key Biologics announced their partnership for the collection of mononuclear cells (MNCs) by leukapheresis, which includes joint donor recruitment, marketing, and product distribution. The companies also announced that they would provide vital blood products and materials to biotech, pharma, and academic researchers for product manufacturing and research activities. In another instance, in May 2021, AfflyImmune Therapeutics announced that their fast track designation to CAR T-cell agent, AIC100 was granted approval by Food and Drug Administration (FDA). The procedure is for treating patients with anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.

Increasing prevalence of cancer and rising geriatric population are also expected to contribute to market growth. However, high costs of treatment can restrain the market during the forecast period. Also, stringent donor selections can further hamper market augmentation. The increasing investments in research & development activities to lower the treatment costs and providing therapies in emerging countries are expected to create opportunities for the market. However, blood transfusion safety in developing economies can be challenging for the market.

TABLE 1: GLOBAL LEUKAPHERESIS MARKET OVERALL SNAPSHOT

TABLE 1: GLOBAL LEUKAPHERESIS MARKET OVERALL SNAPSHOT

Segmentation

The global leukapheresis market report has been segmented by type, application, and end user, and the leukopaks market is segmented by type, indication, end user and region.

FIGURE 2: GLOBAL LEUKAPHERESIS MARKET SEGMENTATION

FIGURE 2: GLOBAL LEUKAPHERESIS MARKET SEGMENTATION

Global Leukapheresis Market, by Type

Based on type, the leukapheresis market is divided into leukapheresis disposables and leukapheresis devices. The leukapheresis devices segment is expected to be the fastest-growing segment during the forecast period. Leukapheresis devices are further classified as centrifugal devices and membrane separators. Centrifugal device separates blood or plasma components from whole blood for depletion or exchange of these components or plasma. The rising demand for disposables and recurrent usage are expected to drive segment growth during the forecast period. The installation of centrifugal devices for therapeutic apheresis is estimated to augment the segment growth.

Global Leukapheresis Market, by Application

Based on application, the leukapheresis market is segmented into research applications and therapeutic applications. The research applications segment is expected to be the fastest-growing segment during the forecast period. Rising research and development activities by various organizations are expected to contribute to the research applications segment. Furthermore, increasing clinical trials and adoption of leukapheresis procedures for leukemia treatment are also expected to contribute to segment growth.

Global Leukapheresis Market, by End User

Based on end user, the leukapheresis market is divided into blood component providers and blood centers, academic and research institutes, pharmaceutical and biotechnology companies, and hospital and transfusion centers. The blood component providers and blood centers segment is expected to hold the largest market share during the forecast period. The demand for blood and plasma donation is increasing, which is expected to boost the blood component & blood centers segment.

The academic and research institutes segment is expected to observe significant growth during the analysis period due to rising partnerships and collaborations for researching cell-based cancer therapies. For instance, Partner Therapeutics, a biotech company, announced the investigator-initiated clinical trial results for evaluating the use of Leukine in patients with Alzheimer’s disease. Various professors and collaborators at the University of Colorado also published their findings in Alzheimer’s & Dementia.

Global Leukopaks Market, by Type

Based on type, the leukopaks market is divided into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs. The mobilized leukopaks segment is expected to hold the largest market share during the forecast period. Mobilized leukopaks are collected from healthy blood donors to stimulate the mobilization of cells with approved drugs. The demand for immunotherapy, transplant therapy, and regenerative therapy, is expected to drive the mobilized leukopaks segment growth during the forecast period.

The non-mobilized leukopaks segment is expected to observe significant growth during the forecast period due to its low cost. Non-mobilized leukopaks are used to harvest lymphocyte and monocytes to be used in various therapeutic regimes. Diseased leukopaks will support the market growth due to growing adoption of diseases leukopaks for cell interaction and toxic studies. Furthermore, rising research & development activities on cell-based therapies will drive the isolated PBMCs.

Global Leukopaks Market, by Indication

Based on indication, the leukopaks market is divided into acute lymphocytic leukemia, multiple myeloma, non-Hodgkin’s lymphoma, chronic lymphocytic lymphoma, pancreatic cancer, hepatocellular carcinoma, and other. The pancreatic cancer segment is expected to be the fastest growing segment during the forecast period. Increasing age and medical conditions like diet, obesity, diabetes, inheritance and rare conditions can lead to pancreatic cancer. Additionally, external factors like smoking and consuming alcohol can also lead to pancreatic cancer. According to World Cancer Research Fund, in 2018, 460,000 new pancreatic cancer cases were reported. Thus, the increase in pancreatic cases is expected to contribute to segment growth.

Diseases like lymphocytic leukemia, pancreatic cancer, non-Hodgkin’s lymphoma and others are also associated with increasing age. Thus, the growing geriatric population is another significant factor contributing to the market growth.

Global Leukopaks Market, by End User

Based on end user, the leukopaks market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations. The pharmaceutical and biotechnology companies segment is expected to hold the largest market share during the forecast period. Growing demand for drug development and therapies using leukopaks as starting material will boost the pharmaceutical & biotechnology companies segment.

The academic and research institutes segment is expected to observe significant growth during the forecast period due to rising partnerships and collaborations for researching cell-based cancer therapies. The growing demand for clinical trials and sponsorships will drive the contract research organizations segment during the forecast period. For instance, in October 2020, Memorial Sloan Kettering Cancer Center in New York was recruiting pleural mesothelioma patients for clinical trials with T-cell therapy. In another instance, FDA lifted the partial clinical hold on CAR T-cell trial of chimeric antigen treatment for metastatic castration-resistant prostate cancer patients in November 2020.

Global Leukapheresis Market, by Region

Based on region, the global leukapheresis market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South America. North America is expected to witness the significant growth in the market during the forecast period. The presence of large number of leading pharmaceutical and biotechnology companies in the region is expected to drive the market during the forecast period.

Rising prevalence of blood cancer will support the market growth. According to American Cancer Society, in the U.S. around 61,090 Americans are expected to be diagnosed with leukemia in 2021. Increasing research & development activities for therapies is another significant factor which will further boost the regional market growth.

TABLE 2: GLOBAL LEUKAPHERESIS MARKET OVERVIEW

TABLE 2: GLOBAL LEUKAPHERESIS MARKET OVERVIEW

FIGURE 3: GLOBAL LEUKAPHERESIS MARKET (USD MILLION), 2021-2030

 FIGURE 3: GLOBAL LEUKAPHERESIS MARKET (USD MILLION), 2021-2030

Recent Developments in the Global Leukapheresis Market

  • July 2021- American Gene Technologies (AGT) announced the continuation of AGT’s HIV cure program after safety analysis which revealed no adverse effects from the treatment. The treatment involves delivering therapeutic genes to recipient’s immune cells where cells have been collected through leukapheresis procedure.
  • June 2021- OrganaBio LLC announced the products related to adult peripheral blood-derived, which include peripheral blood mononuclear cells (PBMCs) and whole leukopaks. The company also stated that products have high concentration of PBMCs like NK cells, T cells, B cells and monocytes.
  • January 2021- Lonza launched the customizable cryopreserved leukopaks. These frozen leukopaks are suitable for long term storage for research activities and allows immediate access to viable cells for workflow flexibility.

What Does This Report Provide?

This report provides a detailed understanding of the global leukapheresis market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market. The major market drivers, challenges, and opportunities for the global leukapheresis market have been covered in the report. This report further includes the market shares of the leading companies operating in the global market, along with their production capacities and the growth strategies adopted by them.

Market Segmentation:

Leukapheresis Market, by Type:

  • Leukapheresis Disposables
  • Leukapheresis Devices
    • Centrifugal Devices
    • Membrane Separators

Leukapheresis Market, by Application:

  • Research Applications
  • Therapeutic Applications

Leukapheresis Market, by End User:

  • Blood Component Providers & Blood Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospital & Transfusion Centers

Leukopaks Market, by Type:

  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks
  • Diseased Leukopaks
  • Isolated PBMCs

Leukopaks Market, by Indication:

  • Acute Lymphocytic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin’s Lymphoma
  • Chronic Lymphocytic Lymphoma
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Other Indications

Leukopaks Market, by End User:

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations

By Region:

North America Leukapheresis Market

  • North America, by Country
    • U.S.
    • Canada
    • Mexico
  • North America, by Leukapheresis Market Type
  • North America, by Leukapheresis Market Application
  • North America, by Leukapheresis Market End User
  • North America, by Leukopaks Market Type
  • North America, by Leukopaks Market Indication
  • North America, by Leukopaks Market End User

Europe Leukapheresis Market

  • Europe, by Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe 
  • Europe, by Leukapheresis Market Type
  • Europe, by Leukapheresis Market Application
  • Europe, by Leukapheresis Market End user
  • Europe, by Leukopaks Market Type
  • Europe, by Leukopaks Market Indication
  • Europe, by Leukopaks Market End User

Asia Pacific Leukapheresis Market

  • Asia Pacific, by Country
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific 
  • Asia Pacific, by Leukapheresis Market Type
  • Asia Pacific, by Leukapheresis Market Application
  • Asia Pacific, by Leukapheresis Market End user
  • Asia Pacific, by Leukopaks Market Type
  • Asia Pacific, by Leukopaks Market Indication
  • Asia Pacific, by Leukopaks Market End User

Middle East and Africa Leukapheresis Market

  • Middle East and Africa, by Country 
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of Middle East and Africa
  • Middle East and Africa, by Leukapheresis Market Type
  • Middle East and Africa, by Leukapheresis Market Application
  • Middle East and Africa, by Leukapheresis Market End user
  • Middle East and Africa, by Leukopaks Market Type
  • Middle East and Africa, by Leukopaks Market Indication
  • Middle East and Africa, by Leukopaks Market End User

South America Leukapheresis Market

  • South America, by Country 
    • Brazil
    • Argentina
    • Rest of South America
  • South America, by Leukapheresis Market Type
  • South America, by Leukapheresis Market Application
  • South America, by Leukapheresis Market End user
  • South America, by Leukopaks Market Type
  • South America, by Leukopaks Market Indication
  • South America, by Leukopaks Market End User

Major Companies: In this report, the major companies studied are: Asahi Kasei Medical Co. Ltd., Fresenius SE & Co. KGaA, Haemonetics Corporation, Terumo BCT, Inc., Macopharma SA, Miltenyi Biotec, Guangzhou Daji Medical Science and Technology Co. Ltd., MEDICA S.p.A, PuriBlood Medical Co. Ltd., Beijing ZKSK, Technology Co. Ltd., Charles River Laboratories, AllCells, LLC, StemExpress, LLC., Caltag Medsystems Limited, Lonza Group AG, ZenBio, Precision for Medicine, BioIVT, Discovery Life Sciences, and Intelligent Tissue Group.

Objectives of this Report:

  • To estimate the market size for the leukapheresis market on a regional and global basis
  • To identify major segments in the leukapheresis market and evaluate their market shares and demand
  • To provide a competitive scenario for the leukapheresis market with major developments observed by the key companies in the historic years
  • To evaluate key factors governing the dynamics of leukapheresis market with their potential gravity during the forecast period
  • To evaluate the leading company-wise pricing analysis for the mentioned applications

Key Questioned Answered in the Study:

  • What are major growth drivers and market trends that impacting on the global leukapheresis market?
  • What the market size both in terms of value and volume for global leukapheresis market?
  • Who are leading market players and who are the new market players that operate in the global leukapheresis market with an estimated market share?
  • What are the future investment pockets and opportunity in the global leukapheresis market?
  • Major list of customers and potential futuristic customer list along with an estimated buying volume
  • Impact of COVID-19 in global leukapheresis market

Customization:

This study is customized to meet your specific requirements:

  • By sub-segment
  • By client-specific country, type, and application market analysis
  • Pricing analysis along with the potential list of customers
  • Product-specific competitive analysis

For more information, contact: sales@quincemarketinsights.com